348 related articles for article (PubMed ID: 27053545)
1. Hospitalizations and economic analysis in psychotic patients with paliperidone palmitate long-acting injection.
Mesones-Peral JE; Gurillo-Muñoz P; Sánchez-Sicilia MP; Miller A; Griñant-Fernández A
Rev Psiquiatr Salud Ment; 2017; 10(1):33-37. PubMed ID: 27053545
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
[TBL] [Abstract][Full Text] [Related]
3. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.
Rosenheck RA; Leslie DL; Sint KJ; Lin H; Li Y; McEvoy JP; Byerly MJ; Hamer RM; Swartz MS; Stroup TS
Psychiatr Serv; 2016 Oct; 67(10):1124-1130. PubMed ID: 27247177
[TBL] [Abstract][Full Text] [Related]
5. Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery.
Williams W; McKinney C; Martinez L; Benson C
J Med Econ; 2016; 19(5):469-76. PubMed ID: 26671481
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.
Xiao Y; Muser E; Fu DJ; Lafeuille MH; Pilon D; Emond B; Wu A; Duh MS; Lefebvre P
Curr Med Res Opin; 2016; 32(4):759-69. PubMed ID: 26750639
[TBL] [Abstract][Full Text] [Related]
7. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study.
Bioque M; Parellada E; García-Rizo C; Amoretti S; Fortea A; Oriolo G; Palau P; Boix-Quintana E; Safont G; Bernardo M
Eur Psychiatry; 2020 Jul; 63(1):e71. PubMed ID: 32669145
[TBL] [Abstract][Full Text] [Related]
8. One year mirror-image study using paliperidone palmitate for relapse prevention of schizophrenia in four university hospitals in Canada.
Vincent PD; Demers MF; Doyon-Kemp V; Duchesneau J; Halme A; Masson V
Schizophr Res; 2017 Jul; 185():96-100. PubMed ID: 28119036
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain.
Einarson TR; Bereza BG; Garcia Llinares I; González Martín Moro B; Tedouri F; Van Impe K
J Med Econ; 2017 Oct; 20(10):1039-1047. PubMed ID: 28678566
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement.
Muser E; Kozma CM; Benson CJ; Mao L; Starr HL; Alphs L; Fastenau J
J Med Econ; 2015; 18(8):637-45. PubMed ID: 25851616
[TBL] [Abstract][Full Text] [Related]
12. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.
Joshi K; Lin J; Lingohr-Smith M; Fu DJ
J Med Econ; 2015; 18(8):629-36. PubMed ID: 25800457
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
14. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse.
Lefebvre P; Muser E; Joshi K; DerSarkissian M; Bhak RH; Duh MS; Shiner B; Young-Xu Y
Clin Ther; 2017 Jul; 39(7):1380-1395.e4. PubMed ID: 28641996
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.
Einarson TR; Pudas H; Goswami P; van Impe K; Bereza BG
J Med Econ; 2016; 19(2):111-20. PubMed ID: 26414966
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
Einarson TR; Vicente C; Zilbershtein R; Piwko C; Bø CN; Pudas H; Jensen R; Hemels ME
Nord J Psychiatry; 2014 Aug; 68(6):416-27. PubMed ID: 24274837
[TBL] [Abstract][Full Text] [Related]
17. Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia.
Basu A; Benson C; Alphs L
J Manag Care Spec Pharm; 2018 Aug; 24(8):759-768. PubMed ID: 30058979
[TBL] [Abstract][Full Text] [Related]
18. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics.
Baser O; Xie L; Pesa J; Durkin M
J Med Econ; 2015 May; 18(5):357-65. PubMed ID: 25525771
[TBL] [Abstract][Full Text] [Related]
19. Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain.
Quintero J; Oyagüez I; González B; Cuervo-Arango I; García I; Casado MA
Clin Drug Investig; 2016 Jun; 36(6):479-90. PubMed ID: 27000061
[TBL] [Abstract][Full Text] [Related]
20. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
Lin D; Thompson-Leduc P; Ghelerter I; Nguyen H; Lafeuille MH; Benson C; Mavros P; Lefebvre P
CNS Drugs; 2021 May; 35(5):469-481. PubMed ID: 33909272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]